NexPlasmagen Inc.
2008 -
NexPlasmaGen Inc (NPG) was founded in 2008 by Ms Valérie Léveillé in order to develop and commercialize a revolutionary technology for the treatment of chronic wounds and skin diseases. The technology generates a plasma, a mixture of very reactive ionized gases, with strong sterilizing potential. The treatment with this new technology is precise, non-invasive and thus has the potential to not generate secondary effects. In addition, the technology is compact and portable and thus can be used by hospitals, nursing homes, clinics in isolated communities, military outposts and even at the patient home. NPG has an option to negotiate a license on the technology with McGill University. The company is currently in pre-incubation period at the QBIC and is validating the technology performances for the treatment of chronic wounds.
3801 avenue Wilson, Montréal, Quebec H4A 2T7
Téléphone : (514) 917-3796
Website : www.nexplasmagen.com
![]()
Novagenesis inc.
2013 -
500, Cartier blvd. West, office 133A, Laval (Quebec) H7V 5B7
Oligo Medic inc.
2011 -
Oligo Medic is a Medical Device company, based in the great Montreal area, Quebec, working at the design, development and marketing of specialized Medical Devices. Oligo Medic developed its expertise around injectable devices, biopolymeric devices, and reparative musculo-skeletal and wound healing devices. Its main product platform is devoted to the arthroscopic treatment of articular cartilages.
500 Cartier blvd. West, Office 113,
Laval, Québec H7V 5B7
Phone : (450) 680-3371
Website : www.oligomedic.com
Thrasos Innovation inc.
2011 -
Thrasos Innovation is a clinical stage bio-therapeutics company focused on the discovery and development of targeted therapies for the prevention and treatment of severe organ failure, with a principle focus on kidney disease. The Company's first drug candidates are being developed for the treatment of two critical medical needs: the prevention and treatment of Acute Kidney Injury (AKI) and the treatment of fibrosis due to diabetic nephropathy in Chronic Kidney Disease (CKD). THR-184, the drug candidate for AKI will enter phase II clinical trial in the second half of 2012.
500, Cartier West Blvd., Suite 203 Laval (Québec) H7V 5B7
Phone : (514) 940-2714 | Fax : (514) 284-1054
Website : www.thrasos.com